Unilever's £50bn offer for the consumer healthcare arm of GlaxoSmithKline (GSK) has been rejected - but this feels like the start of what could turn out to be a protracted takeover battle. Read The Rest at :
Disclaimer : The Money republic collects data cautiously before publishing any information. The Money republic is not responsible for the authenticity, adequacy or integrity of any fact, data or information. Hence we are not liable for any kind of problem created by the use of such information.
